Keyphrases
Genomic Analysis
100%
Drug Screening
100%
Trastuzumab
100%
Breast Cancer Cell Lines
100%
Screening Analysis
100%
HER2-positive Breast Cancer
100%
Treatment Response
100%
Kinase Inhibitor
50%
Lapatinib
50%
Breast Cancer
50%
Molecular Features
50%
Retarding Effect
50%
AKT Pathway
50%
AKT1
50%
Cell Viability
25%
Commercially Available
25%
Molecular Mechanism
25%
Expression Level
25%
Human Epidermal Growth Factor Receptor 2 (HER2)
25%
Druggability
25%
Transcriptomic Profiling
25%
Target Molecule
25%
PLCG1
25%
Treatment Sensitivity
25%
HER2 Amplification
25%
Cdc42
25%
MAPK8
25%
Signaling Pathway
25%
Response Predictors
25%
Two-cell
25%
PAK6
25%
Inhibitor Response
25%
Drug Sensitivity
25%
Therapy Decision
25%
PTK6
25%
PIK3CA mutation
25%
Genomic Profiling
25%
Poor Prognosis
25%
PIK3CA
25%
ErbB2
25%
ErbB2 Signaling
25%
Signaling Molecular
25%
Alternative Therapeutics
25%
INIS
drugs
100%
screening
100%
cancer
100%
breasts
100%
sensitivity
75%
growth
50%
kinases
50%
mutations
50%
comparative evaluations
25%
levels
25%
proteins
25%
viability
25%
patients
25%
genes
25%
losses
25%
amplification
25%
therapy
25%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Drug Screening
100%
Trastuzumab
100%
Genomics
100%
Signal Transduction
75%
Lapatinib
50%
Akt Signaling
50%
Kinase
50%
Phosphotransferase
50%
Targeting Protein
25%
CDC42
25%
Transcriptomics
25%
Cell Viability
25%
Drug Sensitivity
25%
MAPK8
25%
Medicine and Dentistry
Treatment Response
100%
Breast Cancer Cell Line
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Drug Screening
100%
Cell Line
100%
Signal Transduction
60%
Akt Signaling
40%
Growth Retardation
40%
Breast Cancer
40%
Phosphotransferase Inhibitor
40%
Cell Viability
20%
Drug Sensitivity
20%
Transcriptomics
20%
Targeting Protein
20%
Immunology and Microbiology
Drug Screening
100%
Cell Line
100%
Breast Cancer Cell Line
100%
Trastuzumab
80%
Signal Transduction
60%
Akt Signaling
40%
Transcriptomics
20%
Drug Sensitivity
20%
Cell Viability
20%
Protein Targeting
20%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Screening
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Trastuzumab
100%
Growth Retardation
50%
Phosphotransferase Inhibitor
50%
Breast Cancer
50%
Lapatinib
50%
Cell Viability
25%